Showing 3501-3510 of 4164 results for "".
- EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Aca
- EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 5
- SIFI Announces Expansion in the French Market With Acquisition of Dacudoses and Novoptinehttps://modernod.com/news/sifi-announces-expansion-in-the-french-market-with-acquisition-of-dacudoses-and-novoptine/2479574/Italian ophthalmic company SIFI has announced the acquisition of Dacudoses and Novoptine antiseptic brands in France from Laboratoire Gifrer Barbezat. Terms of the deal were not disclosed. Dacudoses is the leading reimbursed RX brand of the French ophthalmic antiseptic segment, pres
- EyePoint Pharmaceuticals Presents Positive Yutiq 36-Month Follow-Up Phase 3 Data at ARVOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutiq-36-month-follow-up-phase-3-data-at-2019-arvo-annual-meeting/2476523/EyePoint Pharmaceuticals announced the presentation of 36-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18-mg micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The data
- EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-yutiq/2476328/EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in
- EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutuq-24-month-follow-up-data-at-aao/2479724/EyePoint Pharmaceuticals announced the presentation of 24-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Th
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i
- Study Examines Using Re-Esterified Omega-3 and Maqui Berry in Combination as a Treatment for Dry Eye Diseasehttps://modernod.com/news/study-examines-using-re-esterified-omega-3-and-maqui-berry-in-combination-as-a-treatment-for-dry-eye-disease/2476402/Focus Laboratories has announced that a clinical study on their VitaSight O3+Maqui Dietary Supplement, conducted by Edward Paul, PhD, was published in the Journal of Clinical & Experiment
- Kowa Initiates Phase 3 Safety Trial for Glaucoma Drug Candidate NCX 470 in Japanhttps://modernod.com/news/kowa-initiates-phase-3-safety-trial-for-glaucoma-drug-candidate-ncx-470-in-japan/2482918/Nicox announced that its exclusive Japanese partner, Kowa, has officially initiated a phase 3 safety clinical trial for NCX 470 (also referred to as K-911) in Japan. NCX 470 is Nicox’s lead clinical candidate, currently undergoing phase 3 clinical evaluations
- Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitishttps://modernod.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/Marinomed Biotech has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis. The results, now published in the peer-reviewed journal Clinical Ophthalmology, indicate that Tacrosolv, formulated usin